Compare Charles River Laboratories Intl. Inc (CRL) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Kingsoft Cloud Holdings Limited — how do they compare? Charles River Laboratories Intl. Inc trades at $287.33 (market cap $13.46B), while Kingsoft Cloud Holdings Limited trades at $11.7 (market cap $3.53B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.8× Kingsoft Cloud Holdings Limited's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals.
| CRL | KC | |
|---|---|---|
Market Cap | $13.46B | $3.53B |
Sector | Health | Technology |
52-Week High | $282.00 | $18.21 |
52-Week Low | $145.57 | $8.58 |
Enterprise Value | $16.30B | $3.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Kingsoft Cloud (KC) trades at $11.67, down 2.42% today, amid a bullish technical signal with strong analyst support. The company shows robust revenue growth, with Q1 2026 sales up 37% year-over-year, but remains unprofitable with a net margin of -9.39%. Recent news highlights AI-driven growth, with AI cloud billing now surpassing half of public cloud revenue, fueling positive sentiment.
KC presents a high-risk, high-reward opportunity. The bullish analyst consensus (70% buy ratings) and AI expansion offer significant upside potential, but persistent losses, high debt, and China regulatory risks pose substantial threats. Profitability improvement is critical for sustaining investor confidence and justifying current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
